Allison Bratzel
Stock Analyst at Piper Sandler
(2.29)
# 1,161
Out of 4,479 analysts
25
Total ratings
47.37%
Success rate
-1.06%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $522 → $535 | $435.49 | +22.85% | 11 | Jun 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 | $7.63 | +266.97% | 2 | Mar 26, 2024 | |
| HUMA Humacyte | Maintains: Neutral | $4 | $5.11 | -21.72% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Upgrades: Overweight | $8 → $20 | $5.96 | +235.57% | 4 | Mar 14, 2024 | |
| ROIV Roivant Sciences | Initiates: Overweight | $20 | $10.56 | +89.39% | 1 | Jan 5, 2024 | |
| ABCL AbCellera Biologics | Assumes: Overweight | $20 | $2.77 | +622.02% | 1 | Oct 13, 2023 | |
| REPL Replimune Group | Assumes: Overweight | $44 | $8.37 | +425.69% | 1 | Apr 17, 2023 | |
| RIGL Rigel Pharmaceuticals | Assumes: Neutral | $2 | $8.42 | -76.25% | 1 | Apr 3, 2023 | |
| INCY Incyte | Maintains: Overweight | $100 | $59.02 | +69.43% | 2 | Feb 8, 2023 |
argenx SE
Jun 24, 2024
Maintains: Overweight
Price Target: $522 → $535
Current: $435.49
Upside: +22.85%
Scholar Rock Holding
Mar 26, 2024
Maintains: Overweight
Price Target: $28
Current: $7.63
Upside: +266.97%
Humacyte
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $5.11
Upside: -21.72%
Solid Biosciences
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.96
Upside: +235.57%
Roivant Sciences
Jan 5, 2024
Initiates: Overweight
Price Target: $20
Current: $10.56
Upside: +89.39%
AbCellera Biologics
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.77
Upside: +622.02%
Replimune Group
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $8.37
Upside: +425.69%
Rigel Pharmaceuticals
Apr 3, 2023
Assumes: Neutral
Price Target: $2
Current: $8.42
Upside: -76.25%
Incyte
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $59.02
Upside: +69.43%